Investigational drug · Phase 2
LY03020
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Schizophrenia.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "LY03020"
First trial start
2026
Mar 31, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LY03020", any sponsor or status.
Conditions studied
As listed on its trial records.
- Schizophrenia
Approved drugs for the same conditions: Schizophrenia · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "LY03020" as an intervention, largest first.
- A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With SchizophreniaPivotal-lookingNot yet recruiting
Luye Pharma Group Ltd.Industry
NCT07396870 · 160 participants (planned) · Start Mar 31, 2026 · Primary completion Dec 31, 2027
Drug: LY03020; Placebo · For: Schizophrenia
Sites: Beijing, China
Luye Pharma Group Ltd.Industry
NCT06556966 · 66 participants · Start Aug 19, 2024 · Primary completion Feb 13, 2025
Drug: LY03020; Placebo · For: Schizophrenia; Alzheimer's Disease Psychosis
Sites: Beijing, China
Luye Pharma Group Ltd.Industry
NCT07230652 · 40 participants (planned) · Start Aug 20, 2025 · Primary completion Dec 31, 2025
Drug: LY03020; Placebo · For: Schizophrenia; Alzheimer's Disease Psychosis
Sites: Beijing, China
- A Food Effect Study of LY03020 in Healthy SubjectsActive, not recruiting
Luye Pharma Group Ltd.Industry
NCT07292233 · 16 participants · Start Jul 30, 2025 · Primary completion Aug 27, 2025
Drug: LY03020 · For: Schizophrenia; Alzheimer's Disease Psychosis
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Schizophrenia
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- SEP-363856UlotarontPhase 37 trials
Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder
- NBI-1117568Phase 35 trials
Neurocrine Biosciences · Schizophrenia, Bipolar I Disorder, Mania
- LB-102Phase 34 trials
LB Pharmaceuticals Inc. · Schizophrenia, Bipolar I Disorder
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- OLZSAM, ALKS 3831Phase 32 trials
Alkermes, Inc. · Bipolar I Disorder, Schizophrenia
- B2227Phase 31 trial
Bostal Drug Delivery Co., Ltd · Schizophrenia
- ML-007C-MAPhase 24 trials
MapLight Therapeutics · Psychosis Associated With Alzheimer's Disease, Schizophrenia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.